Enara Bio has raised $32.5m in a Series B financing round to advance its platform shining a light on cancer-specific antigens ...

Gilead Sciences has announced the signing of voluntary licencing agreements with six generic pharmaceutical manufacturers to ...

Health care stocks underperformed the broader market in 2023, with many companies falling short of their profit targets, and ...

Emcure Pharmaceuticals on Thursday said it has signed a royalty-free voluntary licensing agreement with Gilead Sciences ...

Gilead Sciences signs voluntary licensing agreement with six pharma firms to produce generic lenacapavir: Our Bureau, New Delhi Thursday, October 3, 2024, 11:30 Hrs [IST] US-based ...

Dr. Reddy's, Hetero, and Mylan partner with Gilead Sciences to manufacture generic lenacapavir for HIV prevention globally.

The U.S.-based drugmaker also plans to provide the companies branded version of the drug, lenacapavir, in 18 countries, such ...

Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV ...

Dr Reddy's Laboratories and Hetero sign non-exclusive, royalty-free agreements with Gilead Sciences to manufacture ...

Dr Reddy's Laboratories and Hetero, along with other generic drug makers, enter into voluntary licensing agreements with ...

The situation remains at a stalemate following the first day of a historic strike by the International Longshoremen’s ...

Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; ...